Literature DB >> 9108418

TRA1, a novel mRNA highly expressed in leukemogenic mouse monocytic sublines but not in nonleukemogenic sublines.

T Kasukabe1, J Okabe-Kado, Y Honma.   

Abstract

Mouse monocytic Mm-A, Mm-P, Mm-S1, and Mm-S2 cells are sublines of mouse monocytic and immortalized Mm-1 cells derived from spontaneously differentiated, mouse myeloblastic M1 cells. Although these subline cells retain their monocytic characteristics in vitro, Mm-A and Mm-P cells are highly leukemogenic to syngeneic SL mice and athymic nude mice, whereas Mm-S1 and Mm-S2 cells are not or are only slightly leukemogenic. To better understand the molecular mechanisms of these levels of leukemogenicity, we investigated putative leukemogenesis-associated genes or oncogenes involved in the maintenance of growth, especially in vivo, by means of differential mRNA display. We isolated a fragment clone (15T01) from Mm-P cells. The mRNA probed with 15T01 was expressed at high levels in leukemogenic Mm-P and Mm-A cells but not in nonleukemogenic Mm-S1 and Mm-S2 cells. The gene corresponding to 15T01, named TRA1, was isolated from an Mm-P cDNA library. The longest open reading frame of the TRA1 clone predicts a peptide containing 204 amino acids with a calculated molecular weight of 23,049 D. The predicted TRA1 protein is cysteine-rich and contains multiple cysteine doublets. A putative normal counterpart gene, named NOR1, was also isolated from a normal mouse kidney cDNA library and sequenced. NOR1 cDNA predicts a peptide containing 234 amino acids. The sequence of 201 amino acids from the C-terminal NOR1 was completely identical to that of TRA1, whereas the remaining N-terminal amino acids (33 amino acids) were longer than that (3 amino acids) of TRA1 and the N-terminus of NOR1 protein contained proline-rich sequence. A similarity search against current nucleotide and protein sequence databases indicated that the NOR1/TRA1 gene(s) is conserved in a wide range of eukaryotes, because apparently homologous genes were identified in Caenorhabditis elegans and Saccharomyces cerevisiae genomes. Northern blotting using TRA1-specific and NOR1-specific probes indicated that TRA1 mRNA is exclusively expressed in leukemogenic but not in nonleukemogenic Mm sublines and normal tissues and also indicated that NOR1 mRNA is expressed in normal tissues, especially in kidney, lung, liver, and bone marrow cells but not in any Mm sublines. After leukemogenic Mm-P cells were induced to differentiate into normal macrophages by sodium butyrate, the normal counterpart, NOR1, was expressed, whereas the TRA1 level decreased. Furthermore, transfection of TRA1 converted nonleukemogenic Mm-S1 cells into leukemogenic cells. These results indicate that the TRA1 gene is associated at least in part with the leukemogenesis of monocytic Mm sublines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108418

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Identification of phospholipid scramblase 1 as a biomarker and determination of its prognostic value for colorectal cancer.

Authors:  Yung-Bin Kuo; Chung-Chuan Chan; C Allen Chang; Chung-Wei Fan; Ray-Ping Hung; Ya-Shu Hung; Kuei-Tien Chen; Jau-Song Yu; Yu-Sun Chang; Err-Cheng Chan
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

2.  Phospholipid scramblase 1 potentiates the antiviral activity of interferon.

Authors:  Beihua Dong; Quansheng Zhou; Ji Zhao; Aimin Zhou; Ronald N Harty; Santanu Bose; Amiya Banerjee; Roger Slee; Jeanna Guenther; Bryan R G Williams; Therese Wiedmer; Peter J Sims; Robert H Silverman
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 3.  Phospholipid scramblase 1: a protein with multiple functions via multiple molecular interactors.

Authors:  Jessica Dal Col; Marìa Julia Lamberti; Annunziata Nigro; Vincenzo Casolaro; Elisabetta Fratta; Agostino Steffan; Barbara Montico
Journal:  Cell Commun Signal       Date:  2022-06-01       Impact factor: 7.525

4.  Adiposity, dyslipidemia, and insulin resistance in mice with targeted deletion of phospholipid scramblase 3 (PLSCR3).

Authors:  Therese Wiedmer; Ji Zhao; Lilin Li; Quansheng Zhou; Andrea Hevener; Jerrold M Olefsky; Linda K Curtiss; Peter J Sims
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-24       Impact factor: 11.205

5.  Phospholipid scramblase 1 amplifies anaphylactic reactions in vivo.

Authors:  Asma Kassas-Guediri; Julie Coudrat; Emeline Pacreau; Pierre Launay; Renato C Monteiro; Ulrich Blank; Nicolas Charles; Marc Benhamou
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

6.  Blockade of phospholipid scramblase 1 with its N-terminal domain antibody reduces tumorigenesis of colorectal carcinomas in vitro and in vivo.

Authors:  Chung-Wei Fan; Chun-Yu Chen; Kuei-Tien Chen; Chia-Rui Shen; Yung-Bin Kuo; Ya-Shan Chen; Yeh-Pin Chou; Wei-Shan Wei; Err-Cheng Chan
Journal:  J Transl Med       Date:  2012-12-24       Impact factor: 5.531

7.  Nuclear interactions of topoisomerase II alpha and beta with phospholipid scramblase 1.

Authors:  Jessica P Wyles; Zhongqin Wu; Shelagh E L Mirski; Susan P C Cole
Journal:  Nucleic Acids Res       Date:  2007-06-12       Impact factor: 16.971

8.  Differential expression profiling of head and neck squamous cell carcinoma (HNSCC).

Authors:  F Lemaire; R Millon; J Young; A Cromer; C Wasylyk; I Schultz; D Muller; P Marchal; C Zhao; D Melle; L Bracco; J Abecassis; B Wasylyk
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

9.  Regulation of the tyrosine phosphorylation of Phospholipid Scramblase 1 in mast cells that are stimulated through the high-affinity IgE receptor.

Authors:  Asma Kassas; Ivan C Moura; Yumi Yamashita; Jorg Scheffel; Claudine Guérin-Marchand; Ulrich Blank; Peter J Sims; Therese Wiedmer; Renato C Monteiro; Juan Rivera; Nicolas Charles; Marc Benhamou
Journal:  PLoS One       Date:  2014-10-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.